Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться

Boehringer Ingelheim

Специалисты компании

Личные визитки людей, которые сами указали это место работы и разрешили показ здесь. Имена из реестров мы не берём.

Пока никто не показал здесь свою визитку.

Работаете здесь? Покажите свою визитку: фото, должность, кнопка «Написать». Почту и телефон не показываем. Только с вашего разрешения, убрать можно в любой момент. Я здесь работаю — показать мою визитку

Нашли ошибку или чужую визитку? Сообщить модератору

4
исследования идут сейчас
84
исследования в базе
79
Россия
5
Казахстан · идут 4

Разрешения по годам

Новые препаратыБиоэквивалентность

Фазы

Фаза I 2
Фаза II 12
Фаза II–III 1
Фаза III 48
Фаза IV 9
Завершено Фаза III Россия
Placebo; Linagliptin · Boehringer Ingelheim

A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of Linagliptin (5 mg), Administered Orally Once Daily for at Least 52 Weeks in Type 2 Diabetic Patients in Combination With Basal Insulin Therapy

1 263 участника во всех странах ClinicalTrials.gov 1218.36
Завершено Фаза III Россия
tiotropium; placebo · Boehringer Ingelheim

A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).

5 993 участника во всех странах ClinicalTrials.gov 205.235
Завершено Фаза IV Россия
Tiotropium plus Salmeterol; Fluticasone/Salmeterol · Boehringer Ingelheim

Effect of Inhalation of a Free Combination of Tiotropium Once Daily 18 Mcg and Salmeterol Twice Daily 50 Mcg Versus a Fixed Combination of Fluticasone and Salmeterol Twice Daily (500/50 Mcg) on Static Lung Volumes and Exercise Tolerance in COPD Patients (a Randomised, Double-blind, Double Dummy, 16 (2 x 8) Weeks, Crossover Study).

344 участника во всех странах ClinicalTrials.gov 205.334
Завершено Фаза III Россия
linagliptin; placebo · Boehringer Ingelheim

A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg) Administered Orally Once Daily Over 24 Weeks, With an Open-label Extension to One Year (Placebo Patients Switched to BI 1356), in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With a Sulphonylurea

1 058 участников во всех странах ClinicalTrials.gov 1218.18
Завершено Фаза IV Россия
tiotropium 18 mcg; Placebo · Boehringer Ingelheim

A Randomized, Double-blind, Placebo-controlled Two-year Trial to Examine the Changes in Exercise Endurance and COPD Treated With Tiotropium Once Daily (EXACTT)

519 участников во всех странах ClinicalTrials.gov 205.368
Завершено Фаза III Россия
Humira®; BI 695501 · Boehringer Ingelheim

VOLTAIRE-X: Pharmacokinetics, Safety, Immunogenicity and Efficacy of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: a Randomized, Double-blind, Parallel-arm, Multiple-dose, Active Comparator Trial

Санкт-Петербург 2 центра 259 участников во всех странах ClinicalTrials.gov 1297-0009
Завершено Фаза III Россия
Placebo; Paclitaxel; BIBF 1120; Carboplatin; Paclitaxel; Carboplatin · Boehringer Ingelheim

Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

1 366 участников во всех странах ClinicalTrials.gov 1199.15
Завершено Фаза III Россия
Placebo; Pramipexole · Boehringer Ingelheim

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

511 участников во всех странах ClinicalTrials.gov 248.633
Прекращено Фаза II Россия
TPV500mg/RTV200mgBID; TPV500mg/RTV100mgBID; LPV400mg/RTV100mgBID · Boehringer Ingelheim

A Randomised, Open Label, Active Controlled Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir Plus 100 mg or 200 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Comparison to 400 mg Lopinavir Plus 100 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Antiretroviral Therapy Naive Patients for 48 With Extension up to 156 Weeks

Москва, Санкт-Петербург 2 центра 562 участника во всех странах ClinicalTrials.gov 1182.33
Завершено Фаза I Здоровые добровольцы Россия
Lasolvan tablet; Lasolvan tablet; Lasolvan tablet; Lasolvan tablet; Lasolvan effervescent tablet; Lasolvan effervescent tablet; Lasolvan effervescent tablet; Lasolvan prolonged-release hard capsule; Lasolvan prolonged-release hard capsule; Lasolvan prolonged-released capsules; Lasolvan tablet; Lasolvan tablet; Lasolvan prolonged-release hard capsule; Lasolvan effervescent tablet; Lasolvan prolonged-release hard capsule; Lasolvan prolonged-release hard capsule; Lasolvan effervescent tablet; Lasolvan effervescent tablet · Boehringer Ingelheim

An Open-label, Randomised, Multiple-dose, Three-period Crossover Study in Healthy Male and Female Volunteers to Characterise Pharmacokinetics and Assess the Relative Bioavailability of Two New Oral Formulations of Ambroxol Hydrochloride as Lasolvan® Prolonged-release Hard Capsules 75 mg and Lasolvan® Effervescent Tablets 60 mg Compared to Lasolvan® Tablets 30 mg.

24 участника во всех странах ClinicalTrials.gov 18.510
Завершено Россия
248.657 · Boehringer Ingelheim

Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life

1 703 участника во всех странах ClinicalTrials.gov 248.657
Завершено Фаза II Россия
BI 10773; Metformin; BI 10773; Sitagliptin · Boehringer Ingelheim

A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 10773 as Monotherapy or in Combination With Metformin in Type 2 Diabetic Patients

660 участников во всех странах ClinicalTrials.gov 1245.24
Завершено Фаза II Россия
low dose BIBF1120 once daily; low dose BIBF 1120 twice daily; intermediate dose BIBF 1120 twice daily; high dose BIBF 1120 twice daily; placebo · Boehringer Ingelheim

A 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pulmonary Fibrosis, With Optional Active Treatment Extension Until Last Patient Out.

432 участника во всех странах ClinicalTrials.gov 1199.30
Завершено Фаза III Россия
Tiotropium Inhalation Solution · Boehringer Ingelheim

A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

1 007 участников во всех странах ClinicalTrials.gov 205.255
Завершено Фаза III Россия
tiotropium 5mcg/day; placebo · Boehringer Ingelheim

A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma

459 участников во всех странах ClinicalTrials.gov 205.416
Завершено Россия
107.273 · Boehringer Ingelheim

Assessing the Impact of MOVALIS on Health Related Quality of Life

3 569 участников во всех странах ClinicalTrials.gov 107.273
Завершено Фаза III Россия
meloxicam 0.25 mg/kg; meloxicam 0.125 mg/kg; naproxen 10 mg/kg · Boehringer Ingelheim

A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis.

Москва 4 центра 226 участников во всех странах ClinicalTrials.gov 107.208
Завершено Фаза III Россия
Pramipexole; Placebo · Boehringer Ingelheim

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Advanced Parkinson's Disease (PD)

391 участник во всех странах ClinicalTrials.gov 248.634

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.